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Despite optimal suppression of HIV repli-
cation, restoration of CD4 T cells is not
always achieved in antiretroviral therapy–
treated individuals. Defective CD4 recov-
ery in immunologic nonresponders is pos-
sibly associated with TLR-mediated
immune activation driven by alterations
of gut permeability. Hydroxychloroquine
(HCQ) reduces endosomal TLR signaling;
thus, we verified whether HCQ could
dampen immune activation and be associ-
ated with an increase in CD4 T cells. To
this end, we enrolled in a prospective
study 20 HIV-infected immunologic nonre-
sponders (CD4 count < 200 cells/mL or
CD4 increase< 5% in the last 12 months)
who received 400 mg/day HCQ for
6 months. HCQ had a notable impact on
immune activation as shown by signifi-
cant modifications of the following param-
eters: (1) reduced plasma lipopolysaccha-
ride; (2) decreased TLR4-expressing
CD14 cells, TLR4-mediated signal trans-
duction, and mRNA synthesis; (3) re-
duced percentages of activated CD4
(CD4/Ki67) and CD14 (CD14/CD69)
cells; (4) increased T-regulatory cells
(Tregs), naive Tregs, and TLR4-
expressing Tregs; (5) augmented plasma-
cytoid dendritic cells and reduced IFN-
secreting plasmacytoid dendritic cells;
and (6) reduced IL-6 and TNF produc-
tion. HCQ-induced immune modulation
was associated with increased percent-
ages of circulating CD4 T cells and was
mostly retained 2 months after therapy
interruption. HCQ reduces lipopolysac-
charide/TLR-mediated immune activa-
tion; this compound could be a useful
immunomodulant in HIV-infected patients.
This study is registered at EutraCT as
2009-012499-28 with study number HLS01/
2009-1-16-03-2009. (Blood. 2011;118(12):
3263-3272)
Introduction
The antimalarial drug hydroxychloroquine (HCQ) is endowed with
immune modulatory effects including the reduction of inflamma-
tory cytokine production1,2 and of IgG levels and a downmodula-
tion of natural killer cell activity; these properties have warranted
its use in autoimmune conditions including lupus erythematosus,
Sjo¨gren syndrome, and rheumatoid arthritis.3-6 In vitro data,7 as
well as results obtained in a murine model,8 have shown that HCQ
also modulates the intracellular TLR pathway as it reduces TLR9
and TLR4 expression and the CpG DNA- and lipopolysaccharide
(LPS)–mediated activation of NF-B and AP-1. In addition to these
effects, HCQ is characterized by antiviral properties as witnessed by the
ability of this compound to prevent the entry of influenza and adenovi-
ruses into target cells,9 to be an obstacle to retroviral infection in murine
models,10 and to impede HIV-1 replication in vitro.11,12 Of note,
chloroquine decreases Tat-mediated transactivation of HIV-1 LTR in
vitro as well, thereby decreasing HIV-1 production,13 and alters the
immunogenic properties of gp120.14
On the basis of these findings, the use of HCQ has been
evaluated in HIV infection. Results showed that decreases in viral
load, IL-6, and serum IgG titers,15-17 as well as a reduction in
immune activation and a decrease in CD38CD8 T cells and Ki67
memory CD4 T cells18,19 can be observed in HIV-infected patients
receiving HCQ. The effect of this compound on these immune
parameters is important, given that immune activation is believed
to play a key role in HIV pathogenesis.19,20 This suggestion stems
from several observations. Thus, the massive destruction of CD4
T cells in the gastrointestinal mucosa observed in the initial phases
of the infection would provoke severe mucosal alterations, allow-
ing the translocation of products generated by the microbiota in the
systemic circulation. As a consequence, plasma concentrations of
LPS would increase, resulting in TLR-mediated immune activa-
tion.21-23 The triggering of TLR4 by LPS, together with the
stimulation of TLR3 and TLR9 by viral RNA- or DNA-containing
unmethylated CpG dinucleotides, would therefore be the ultimate
culprit of the immune activation observed in HIV infection.22 Of
note, HIV-induced mucosal alterations are suggested to persist over
the whole course of disease, as testified to by the observation that
abnormal LPS plasma concentrations and a degree of activation
involving CD4 and CD8 T lymphocytes are maintained even in
the presence of antiretroviral therapy (ART)–induced suppression
of HIV replication.20
Quantitative CD4 T-cell defects are observed in a percentage
of HIV-infected ART-treated patients (immunologic nonresponders
[INRs]). The pathogenesis of this phenomenon is still unclear, and
several immune alterations were shown to be present in INRs
including: (1) a reduction in CD4 T-memory cell proliferation at
the central level,23 (2) an increased susceptibility of T lymphocytes
to apoptosis,24 (3) higher levels of LPS25 and immune activation,26
and (4) residual viral replication.27-29 These observations led to
therapeutic approaches based either on therapy intensification30,31
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or immunomodulation32 that, nevertheless, did not result in any
significant effect.
We recently reported that lack of proper CD4 T-cell recovery
in HIV-treated patients correlates with LPS-associated and
TLR-mediated immune activation.33 On the basis of these observa-
tions and the ability of HCQ to downregulate TLR-mediated
activation,18 we evaluated whether this compound would have an
effect on immune activation and CD4 T-cell numbers in HIV-
infected INRs.
Methods
Study population
Twenty ART-treated HIV-infected patients with an absolute CD4 count
 200 cells/L during the last 12 months of therapy and with suppressed
viremia ( 37 HIV RNA copies/mL) were consecutively enrolled in the
study. All patients were treated with combined antiretroviral therapy
according to the current guidelines (a nonnucleoside reverse transcriptase
inhibitor plus a protease inhibitor or a nucleoside reverse transcriptase
inhibitor plus a nonnucleoside reverse transcriptase inhibitor). Exclusion
criteria included glucose-6-phosphate dehydrogenase deficit, pregnancy,
breast feeding, acute infectious diseases, or CD4 T-cell count increase
 5% in the last year. All patients received HCQ (400 mg/day) for
6 months. Virologic and immunologic parameters were evaluated at
baseline, at the end of treatment, and at 2 months after HCQ suspension. All
individuals were enrolled by Infectious Diseases Units at Luigi Sacco
Hospital, Milan, Italy, which approved this study; written informed consent
was obtained before enrollment in accordance with the Declaration of
Helsinki.
Blood sample collection and PBMC separation
Whole blood was collected by venipuncture in Vacutainer tubes containing
EDTA (BD Biosciences). Plasma was stored and PBMCs were separated on
lymphocyte separation medium (Cedarlane Laboratories Limited) and
washed twice in PBS (PBI). The number of viable leukocytes was
determined by trypan blue exclusion.
Stimulation of PBMCs
PBMCs were incubated for 18 hours in the presence or absence of a pool of
env  gag peptides (HIV, 2.5M)34 kindly provided by Dr Renato Longhi
(CNR Institute, Milan, Italy). For cytokine analyses, 1 g/mL brefeldin A
(Sigma-Aldrich) was added to the cell cultures 6 hours before cell analyses
to block protein secretion.
Immunophenotypic analysis
Lymphocyte subsets were evaluated using 50 L of EDTA-treated periph-
eral blood incubated for 10 minutes at room temperature with fluorochrome-
labeled mAbs (anti-CD4, -CD8, and -CD14, PECy7; anti-CD14 and
-CD25, PECy5; anti-CD69, allophycocyanine [APC]; anti-HLA-DR, -CD38,
and -TLR4, PE; and anti-CD8, -CD16, -CD45RO, and -TLR2, FITC).
Erythrocyte lysis and fixation of stained cells were performed at the end of
the incubation period using the IMMUNOPREP EPICS Kit and Q-prep
Workstation (Coulter Electronics). Cytometric analyses were performed on
200 000 events using a FC500 flow cytometer (Beckman-Coulter). Green
fluorescence from FITC (FL1) was collected through a 525-nm band pass
filter, red fluorescence from PE (FL2) was collected through a 575-nm band
pass filter, orange fluorescence from phycoerythrin-Texas red (ECD; FL3)
was collected through a 620-nm band pass filter, deep-red fluorescence
from PECy5 (FL4) was collected through a 670-nm band pass filter, red
fluorescence from APC (FL4) was collected through a 650-nm band pass
filter, and far-red fluorescence from PECy7 (FL5) was collected through a
770-nm band pass filter. Linear amplifiers were used for forward and side
scatters and logarithmic amplifiers for FL1, FL2, FL3, FL4, and FL5.
Samples were first run using isotype controls. Flow data were analyzed by
first gating on the lymphocyte and monocyte population as defined by
forward and sidelight scatters. CD4-, CD8-, or CD14-positive cells against
side scatter were then selected and used to evaluate the percentage of
positive cells for the marker analyzed. Data were analyzed using Kaluza 1.1
software (Beckman Coulter).
Ki-67 evaluation
PBMCs were washed in PBS and stained for CD4 PECy7 mAb for
15 minutes at room temperature in the dark before being fixed in 1%
paraformaldehyde (PFA; Sigma-Aldrich) for 15 minutes at 4°C and washed.
Cells were then resuspended in 0.5% saponin (Sigma-Aldrich) and stained
for Ki-67 or mouse FITC-coupled IgG1 (isotype control). After a 45-minute
incubation at 4°C in the dark, cells were washed and fixed in 1% PFA.
Flow data were analyzed by first gating on the lymphocyte population
as defined by forward and sidelight scatters and on CD4 cells. Results
were expressed as the percentage of CD4Ki-67 cells on CD4 population.
Identification of plasmacytoid dendritic cells and
IFN production
Analyses were performed both in basal and stimulated conditions as
described above under “Stimulation of PBMCs.” PBMCs were washed in
PBS, incubated with anti-CD123 PECy7, lineage PECy5 (LIN: anti-
CD3, -CD14, -CD16, -CD19, and -CD56), and anti-HLA DRII PE for
15 minutes, fixed with 1% PFA, incubated for 15 minutes at 4°C in the dark,
washed with PBS, and permeabilized with 0.5% saponin. Anti-IFN mAbs
were then added before a 45-minute incubation at 4°C in the dark. Cells
were then fixed with 1% PFA, and plasmacytoid dendritic cells (pDCs)
were identified by flow cytometry (CD123HLADRLIN); IFN expres-
sion on these cells was evaluated.
TLR4, TLR7, and TLR8 expression on stimulated monocytes
PBMCs were stimulated for 18 hours with LPS (TLR4 agonist; Sigma-
Aldrich) or single-stranded RNA (ssRNA; TLR7 and TLR8 agonist;
InvivoGen). For TLR4, PBMCs were washed with PBS, incubated with
anti-CD14 PC5 and anti-TLR4 PE (eBioscience) mAbs for 15 minutes in
the dark and were subsequently fixed with 1% PFA. For TLR7 and TLR8,
PBMCs were washed with PBS and incubated with anti-CD14 PC5 for
15 minutes in the dark at room temperature. After a second washing, cells
were permeabilized with 0.5% saponin and incubated with anti-TLR8 PE
(Imgenex) and anti-TLR7 FITC (R&D Systems) for 45 minutes at 4°C.
At the end of this incubation, PBMCs were washed with PBS and fixed
with 1% PFA.
Plasma LPS concentration
LPS concentration was measured in plasma with the LAL Chromogenic
Endpoint Assay (Hycult Biotechnology). Samples, prepared according to
the manufacturer’s instructions, were plated in a 96-well plate, followed by
LAL reagent. After a 45-minute incubation at room temperature, absor-
bance was measured (405 nm) with a spectrophotometer. LPS concentra-
tion is expressed in endotoxin units per milliliter and was calculated relative
to a standard curve.
Plasma TNF and IL-6 concentration
Proinflammatory cytokines were evaluated in plasma using commercial
ELISA kits (R&D Systems) following the manufacturer’s instructions.
The plasma concentration of each protein was calculated relative to a
standard curve.
Identification of T-regulatory lymphocytes and of
TLR-expressing T-regulatory lymphocytes
PBMCs were incubated with anti-CD4 PC7, anti-CD25 ECD, and anti-
PD-1 PE for 15 minutes at room temperature.35 The intracellular staining of
PD1 and FoxP3 was performed according to the manufacturer’s instructions
(eBioscience). To detect TLR-expressing T-regulatory cells (Tregs), PBMCs
were stained with CD4 PC7, CD25 ECD, TLR4 PE, and TLR2 FITC mAbs.
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Intracellular staining of FoxP3 was performed according to the manufactur-
er’s instructions (eBioscience).
Intracellular cytokine concentration
Antigen-stimulated PBMCs were stained for CD4 or CD14 expression.
After a 15-minute incubation at room temperature in the dark, cells were
fixed in 1% PFA (Sigma-Aldrich), incubated for 15 minutes at 4°C, and
permeabilized with 0.5% saponin (Sigma-Aldrich). TNF PE, TNF FITC,
and IL-6 mAbs were then added; after a 45-minute incubation at 4°C in the
dark, cells were washed and fixed in 1% PFA (Sigma-Aldrich).
mAbs
The following mAbs were used: anti-CD123 (mouse IgG1 isotype) PECy7
(BioLegend); anti-CD4 (mouse IgG1 isotype), anti-CD8 (mouse IgG1
isotype), and anti-CD14 (mouse IgG2a isotype) PECy7; anti-CD3 (mouse
IgG1 isotype), anti-CD14 (mouse IgG2a isotype), anti-CD16 (mouse IgG1
isotype), anti-CD19 (mouse IgG1 isotype), anti-CD25 (mouse IgG1
isotype), and anti-CD56 (mouse IgG1 isotype) all coupled to PECy5;
anti-CD25 (mouse IgG2a isotype) coupled to ECD; anti-HLADR (mouse
IgG1 isotype) and anti-CD38 (mouse IgG1 isotype) coupled to PE;
anti-CD8 (mouse IgG1 isotype), anti-CD14 (mouse IgG2a isotype), anti-
CD16 (mouse IgG1 isotype), and anti-CD45RO (mouse IgG2a isotype)
coupled to FITC (Beckman-Coulter); anti-TLR4 PE (mouse IgG2a iso-
type), anti-PD1 PE (mouse IgG1 isotype), and anti-TLR2 FITC (mouse
IgG2a isotype); anti-CD69 APC (mouse IgG1 isotype), anti-TLR2 APC
(mouse IgG2a isotype), and anti-TLR4 FITC (mouse IgG2a isotype;
eBioscience); and recombinant protein annexin V PE (Bender MedSys-
tems). The intracellular staining detection mAbs used were anti-Foxp3 (rat
IgG2a isotype) PECy5, anti-PD1 FITC (mouse IgG1 isotype), anti–IL-6
APC (rat IgG1 isotype; BioLegend), anti-human IFNa FITC (mouse IgG1
isotype; PBL), anti-human Ki67 FITC (mouse IgG1 isotype; BD Biosci-
ences); anti-TNF PE (mouse IgG1 isotype; Beckman Coulter), anti-TNF
FITC (rat IgG1 isotype; Caltag Laboratories), anti-TLR7 FITC (mouse
IgG2a isotype; R&D Systems); and anti-TLR8 PE (mouse IgG1 isotype;
Imgenex).
TLR signaling pathway
On the basis of previously published data,36 2.5  105 freshly isolated
PBMCs were incubated for 3 hours with medium alone, LPS (2 g/mL), or
ssRNA40 (2.5 g/mL). mRNA was extracted from PBMCs by using the
acid guanidinium thiocyanate-phenol-chloroform method, dissolved in
RNase-free water, and purified from genomic DNA with RNase-free DNase
(RQ1 DNase, Promega). One milligram of RNA was reverse-transcribed
into first-strand cDNA in a 20-L final volume containing 1M random
hexanucleotide primers, 1M oligo(dT), and 200 U of Moloney murine
leukemia virus reverse transcriptase (Clontech). TLR signaling pathways
were analyzed in a PCR array including a set of optimized real-time PCR
primer assays on 96-well plates (SABiosciences Corporation) using a
SYBR Green PCR mix (Finnzymes). This approach allows the monitoring
of mRNA expression of 84 genes related to TLR pathway activation plus
5 housekeeping genes. Controls were also included on each array for
genomic DNA contamination, RNA quality, and general PCR performance.
Statistical analyses
Data were analyzed according to standard statistical tests; t tests were
performed to compare patients during treatment. Procedures were based on
parametric analyses. The rank-transformed variables were analyzed if
distributions were not normal. Statistical analysis was performed using the
SPSS statistical package (SPSS Inc).
Results
Study population
The clinical and demographic characterization of the patients
enrolled in the study is presented in Table 1. HCQ was well
tolerated in all patients with the exception of one individual who
reported a maculopapular exanthema after 10 days of treatment.
This individual was excluded from the final analyses. HIV viremia
was undetectable throughout the study period.
CD4 T cells
The percentage of CD4 T cells was significantly augmented after
6 months of HCQ treatment (P .001; Figure 1A) without changes
in total lymphocytes counts (Table 1). This increase was retained
2 months after HCQ suspension (P 	 .001). A similar trend was
observed in CD4 T-cell counts, even if changes did not reach
statistical significance (Figure 1B).
Subsets of activated immune cells: CD4 and CD8 T cells and
CD14 monocytes
Immune activation results in the detection in peripheral blood of
increased quantities of subsets of immune cells expressing particu-
lar proteins. To evaluate a possible immunomodulatory effect of
HCQ on this immune activation, we analyzed such subsets in all the
individuals enrolled in the study.
CD4 T-cell activation was evaluated in unstimulated cells and
on HIV-specific stimulation. The percentage of Ki67-expressing
CD4 T cells (activated T cells) was significantly reduced after
6 months of HCQ in both unstimulated and in stimulated condition
(unstimulated, P 	 .005; env gag, P 	 .003; Figure 1C). This
effect was retained 2 months after HCQ interruption (unstimulated,
P 	 .024; env gag, P 	 .044).
The percentage of HLADRII-, CD69-, and CD38/CD45RO-
expressing CD8 T cells decreased as well, albeit not significantly,
after 6 months of HCQ treatment. A different pattern was seen
when these populations were analyzed 2 months after HCQ
interruption. Thus, (1) CD8/DRII cells were significantly re-
duced both in comparison with baseline and with month 6 (P	 .013
Table 1. Clinical and epidemiologic characteristics of HCQ-treated
patients
Parameter
HCQ patients
(n  20)*
Age, y 49.78 
 2.92 (28-68)
Sex (male/female) 14/6
HIV infection 5.33 
 1.38 (1-15)
Duration of ART, y 4.43 
 1.22 (1-15)
Viral load, copies HIV RNA/mL*
Baseline  37
6 mo of HCQ  37
2 mo after HCQ interruption  37
Coinfections, n (%)
HBV 1/20 (5)
HCV 4/20 (20)
CD4 T-cell count nadir, cells/mm3 54.57 
 11.43 (6-112)
CD4 T cells, % 10.68 
 1.07 (3.8-18.2)
CD4 T-cell counts, cells/mm3 143.70 
 13.19 (6-200)
Total lymphocyte count, mean  SE, cells/mm3*
Baseline 1403.33 
 171.07
6 mo of HCQ 1338.33 
 145.25
2 mo after HCQ interruption 1304.45 
 149.65
ART treatment, n
PI 10
NNRTI 7
Other 3
Data are presented as mean 
 SE (range) except where noted.
HBV indicates hepatitis B virus; HCV, hepatitis C virus; NNRTI, nonnucleoside
reverse transcriptase inhibitor; and PI, protease inhibitor
*No significant differences were detected.
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and P 	 .041, respectively, Figure 2A), whereas (2) CD69CD8
and CD38CD45ROCD8 cells were significantly augmented
compared with month 6 (P 	 .043 and P 	 .039, respectively,
Figure 2B-C).
Finally, CD69-expressing CD14 cells were also significantly
reduced after 6 months of HCQ treatment (P 	 .04). Percentages
of these cells returned to the baseline values after 2 months of HCQ
interruption (Figure 2D).
TLR expression on monocytes
HCQ downmodulates the expression of intracellular TLR in vitro
and in the murine model. The effect of this compound in HIV
infection was analyzed by evaluating TLR2, TLR4, TLR5, TLR7,
and TLR8 expression on CD14 cells both in whole blood and on
stimulation with specific antagonist. Results obtained in whole
blood showed that HCQ induced a significant reduction in TLR2-,
TLR4-, and TLR5-expressing CD14 cells (TLR2, P 	 .032;
TLR4, P 	 .004; TLR5, P 	 .008; Figure 3A-C). Results obtained
when cell cultures were stimulated with TLR agonists showed a
significant reduction in LPS-stimulated cells alone (TLR4, P	 .006;
Figure 3D) that vanished 2 months after interruption of HCQ
(P 	 .050). In contrast, no changes in ssRNA-stimulated TLR7-
and TLR8-expressing CD14 cells were detected (Figure 3E-F).
Tregs and TLR-expressing Tregs
Tregs were evaluated both in whole blood and with HIV-specific
stimulation. Both naive (PD1neg) and activated (PD1pos) Tregs were
significantly increased after HCQ; this effect persisted 2 months
after HCQ interruption (Figure 4A-B).
TLR2 and TLR4 expression on Tregs was evaluated in whole
blood and with HIV-specific stimulation; TLR4-expressing Tregs
were also analyzed on LPS stimulation. As shown in Figure 4C
through E, TLR2- and TLR4-expressing Tregs were significantly
augmented after HCQ, and this increase was maintained 2 months
after HCQ suspension in all culture conditions (Figure 4C-E).
Thus, the observed increase in Tregs induced by HCQ was at least
partially supported by TLR2- and TLR4-expressing cells.
pDCs
pDCs represent a unique and crucial immune cell population capable of
producing large amounts of type I IFNs in response to viral infection.
The percentage of pDCs was significantly augmented after 6 months of
HCQ treatment; this effect persisted 2 months after HCQ interruption
(P .001 in both cases; Figure 5A). Of note, IFN-secreting pDCs
were diminished during HCQ treatment and 2 months after HCQ
suspension (P .05 in both cases; Figure 5B).
Figure 1. CD4 T cells in HCQ-treated patients. Percentage of CD4 T cells (A) and CD4 T-cell counts (B) in HIV-infected INRs at baseline (), after 6 months (ms) of HCQ
(u), and 2 months after HCQ interruption (f). Panel C shows unstimulated and env  gag–stimulated activated Ki67CD4 T cells in HIV-infected INRs analyzed at the same
time points. Mean values, SE, and P values are indicated.
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Proinflammatory cytokines
IL-6 and TNF production by CD14 and CD4 T cells was
analyzed in unstimulated and in LPS-, ssRNA-, and env gag–
stimulated conditions; the plasma concentration of these cytokines
was evaluated as well. Results showed IL-6– and TNF-secreting
CD14 and CD4 cells to be diminished after HCQ treatment,
reaching statistical significance only for ssRNA-stimulated CD14
cells (Table 2). The plasma IL-6 concentration was significantly
reduced after HCQ treatment as well (Table 2).
Plasma LPS levels
The plasma LPS concentration is an index of microbial translo-
cation; an augmented LPS concentration is associated with
alterations of the gut permeability. HCQ treatment induced a
reduction in LPS plasma concentration that was maintained after
interruption of therapy (baseline vs 2 months after interruption,
P 	 .03; 6 months HCQ vs 2 months after interruption,
P 	 .001; Figure 6).
TLR signaling pathway
Besides having an effect on TLR expression, HCQ reduces
TLR-mediated signal transduction in vitro and in the murine
model. To evaluate whether a similar effect could be seen in
vivo in HIV-infected patients, TLR-mediated signaling path-
ways were evaluated using an RT-PCR array screening for the
expression of 84 genes involved in such pathways. Engagement
of TLR7/8 with specific agonists at baseline resulted in the
activation of TLR-signaling pathways as demonstrated by
increased expression of mediators involved in the transduction
pathway (MAP2K3, MAP2K4 MAP3K1, MAP3K7,
MAP3K7IP1, MAP4K4, MAPK8, MAPK8IP3, MYD88,
NFKB1, NFKB2, NFKBIA, NFKBIL1, NFRKB, NR2C2, PELI1,
PPARA, PRKRA, REL, RELA, RIPK2, SARM1, SIGIRR,
ECSIT, TBK1, TICAM2, and TIRAP) and of effector molecules
(CSF2, CSF3, IL-12, IL-1, IL-6, IL-10, IL-12, and PTGS2).
After 6 months of HCQ therapy, however, TLR7/8 responsive-
ness was markedly downmodulated, and it was not restored even
after therapy suspension. Of note, TLR7 and TLR8 mRNA
specific expression progressively decreased from baseline to
suspension of HCQ treatment, suggesting a possible explanation
for the decreased responsiveness observed after ssRNA stimula-
tion (Figure 7).
Data collected after TLR4 stimulation resembled the immuno-
logic profile observed in TLR7/8-stimulated PBMCs. Thus, at
baseline PBMCs were highly responsive to LPS, and HCQ therapy
resulted in a marked inhibition of the TLR4 pathway that persisted
after treatment suspension. Similarly to what was observed for
TLR7/8, the gradual decrease in cytokine/chemokine expression
after LPS stimulation was accompanied by reduced expression of
TLR4 mRNA (Figure 7).
Figure 2. Effect of HCQ on activated CD8 T cells and CD14 monocytes. CD8DRII (A), CD8CD69 (B), and CD8CD38CD45RO (C) T cells (percentage) and
CD14CD69 activated monocytes (percentage; D) in HIV-infected INRs at baseline, after 6 months of HCQ, and 2 months after HCQ interruption. Mean values, SE, and P
values are indicated.
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Discussion
The underlying causes of the immune activation seen in HIV
infection are still not fully clarified, but one of the most validated
and solid hypotheses to explain this phenomenon stems from the
observation that acute HIV infection is associated with a rapid and
probably irreversible destruction of the CD4 T cell population that
resides in gut-associated lymphoid tissues.20-23 Loss of mucosal
integrity results in impaired local cellular immunity and transloca-
tion of microbial products, including LPS, which contribute to
persistent inflammation through TLR activation.19-23 Because LPS
ligates TLR4, a molecule expressed on a variety of immune cells,
the LPS/TRL4 axis has been postulated as being responsible for
HIV-associated immune activation. Of note, the non-AIDS comor-
bidities that are more common in ART-treated patients with
persistently reduced CD4T cells despite fully satisfactory suppres-
sion of viral replication (immunologic nonresponders) were re-
cently suggested to be mainly associated with immune activation.
HCQ downregulates TLR signaling and reduces the production
of inflammatory cytokines. On the basis of this assumption we
verified whether this compound could modulate immune activation
and CD4 T-cell counts in INRs. Results herein indicate that HCQ
has a significant effect on immune activation, as shown by the
reduction of circulating activated immune cells, the downmodula-
tion of TLR expression and of TLR-mediated signal transduction,
and the decreased production of IL-6. This effect is probably
associated with the increased concentration of Treg lymphocytes
and the reduced quantities of serum LPS observed in HCQ-treated
individuals and is accompanied by significantly augmented percent-
ages of circulating pDC.
Of note, HCQ-associated reduction of immune activation was
mostly retained after therapy interruption and was accompanied by
a real increase in CD4 T-cell percentage, because total lympho-
cyte counts did not change during the study period. This reduction
of immune activation was also associated with a similar trend,
albeit not reaching statistical significance, in CD4 T-cell counts.
These data suggest that HCQ is effective in reducing CD4 T-cell
activation, resulting in an increase in CD4 T-cell percentage. We
have shown the presence of upregulation of the LPS/TLR-
dependent immune activation in HIV-infected individuals lacking
CD4 normalization during ART,23 and recently a reduction in
immune activation and a decrease in CD38CD8 T cells and of
Ki-67 memory CD4 T cells was reported in ART-treated and naive
HIV-infected patients treated with HCQ.19 Data herein confirm and
expand those results and indicate a possible therapeutic benefit of
HCQ in ART-treated individuals in whom a satisfactory recovery of
CD4 T cells is not achieved.
HCQ was effective in reducing the percentage of proliferating
CD4 T lymphocytes and of activated (CD69) monocytes,
whereas its effect on CD8 T cells was marginal, indicating a
possible lack of effect of HCQ on this lymphocyte population. Of
note, the use of this compound resulted in increased percentages of
circulating Tregs. The role of these cells in HIV infection is still not
totally clarified, but it is likely that the destruction or inactivation of
Tregs by HIV would result in a lack of control over immune
activation.37,38 Treg-mediated suppression of antigen-specific re-
sponses in vitro was shown to be more effective with cells isolated
from relatively healthy HIV-infected individuals compared with
those from patients with later-stage AIDS, suggesting that Tregs
(total or HIV-specific) are depleted and/or dysfunctional later in
HIV disease.39 HCQ treatment induced an increase in naive and
Figure 3. TLR-expressing CD14 monocytes are reduced in HCQ-treated patients. TLR2 (A), TLR4 (B), and TLR5 (C) CD14 monocytes (percentage) in whole blood
in HIV-infected INRs at baseline, after 6 months (ms) of HCQ treatment, and 2 months after HCQ interruption. LPS-stimulated TLR4 (D), ssRNA-stimulated TLR7 (E), and
TLR8 (F) CD14 monocytes (percentage) in the same individuals. Mean values, SE, and P values are indicated.
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activated Tregs in both unstimulated and HIV-infected specific
populations. These subpopulations of Tregs are endowed with
strong immunosuppressive activity and probably play a role in the
ability of HCQ to reduce immune activation. Of note, the increases
in Tregs seen as a result of HCQ were at least partially supported by
TLR2- and TLR4-expressing cells; these subpopulations of Tregs
were shown to mediate a strong immunosuppressive activity.40
HCQ was also associated with an effect on pDC because these
cells were augmented in HCQ-receiving individuals. pDCs are
low-frequency cells found in peripheral blood and lymphoid tissues
that are best known for their ability to produce large quantities of
IFN in response to viruses. An impairment in pDC function was
described in HIV infection and in the pre-ART era pDCs were
shown to inversely correlate with CD4 T counts and viral loads.
Figure 4. Tregs and TLR-expressing Tregs are increased in HCQ-treated patients. Unstimulated (A) and env  gag–stimulated (B) total, naive, and activated Treg (%) in
HIV-infected INRs at baseline, after 6 months (ms) of HCQ treatment, and 2 months after HCQ interruption. Unstimulated (C) and env  gag–stimulated (D) TLR2 and TLR4
Tregs and LPS-stimulated (E) TLR4 Tregs (percentage) in the same patients. Mean values, SE, and P values are indicated.
Figure 5. pDCs are increased in HCQ-treated patients. pDCs (A) and IFN-secreting pDCs (percentage; B) in HIV-infected INR patients at baseline (), after 6 months (ms)
of HCQ treatment (u), and 2 months after HCQ interruption (f). Mean values, SE, and P values are indicated.
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These observations, together with the facts that ART increases pDC
counts and that higher levels of pDC are seen in long-term
nonprogressors, led to the suggestion that pDCs play a protective
role against the progression of HIV infection.41-46 Although IFN
reduces viral burden in the acute phases of infection, elevated
levels of this cytokine in advanced HIV diseases are associated
with increased microbial translocation and could contribute to
immune activation. Of note, despite increasing the number of
pDCs, HCQ reduced IFN production by these cells. IFN
production by pDCs is dependent on TLR9 engagement.18 We did
not directly examine the TLR9 pathway but rather concentrated on
TLR7/8 and TLR4. Nevertheless, because we saw decreased
mRNA synthesis for these 3 TLRs, as well as downregulation of
TLR 7/8 and 4 signaling pathways, it is possible to speculate that
reduced expression of TLR9 on pDCs and/or diminished efficacy
of the TLR9-mediated signaling could justify the reduced IFN
production seen in pDCs of HCQ-treated individuals. In-depth
analyses will be needed to clarify the exact mechanisms. Finally,
whereas pDCs activated through TLR7 and TLR9 work as antiviral
cells via IFN, it was recently suggested that non–IFN-producing
pDCs can act as tolerogenic cells promoting Treg activation via the
indoleamine 2,3-dioxygenase and programmed death 1 pathways.47
Data herein suggest that this phenomenon could take place in vivo
in HCQ-treated individuals.
The use of HCQ resulted also in the downmodulation of IL6
production by immune cells, an effect that was previously shown to
be associated with this drug. More interesting was the reduction of
LPS plasma levels seen in HCQ-treated patients; this observation
suggests an improvement in gut mucosa permeability. It will be
interesting to determine whether this is a direct consequence of
HCQ or rather a consequence of the reduced peripheral immune
activation seen in these patients. These considerations notwithstand-
ing, because LPS directly triggers TLR4-expressing immune cells,
the HCQ-associated reduction of plasmatic LPS probably plays a
major role in the effect on immune activation by HCQ described
herein.
An important caveat of results herein is that the robust reduction
of immune activation achieved by HCQ was not reflected in a
similarly important increase in the absolute number of CD4
T cells: a trend, not a significant amelioration, was observed. This
discrepancy raises several interesting questions: (1) Is the effect of
HCQ not potent enough to convincingly modify CD4 T cells in
patients who are not able to respond immunologically to potent
ART? (2) Is immune activation the only cause responsible for lack
of CD4 T-cell recovery in these patients? And, finally, (3) Will the
immune changes induced by HCQ be sufficient to positively affect
the clinical outcome of these individuals? All the patients are
Table 2. IL6 and TNF production in HCQ-treated patients
Baseline 6 mo of HCQ 2 mo after HCQ interruption P
LPS-stimulated PBMCs, % positive
IL-6CD14 cells 63.94 
 5.91 42.63 
 4.95 62.00 
 5.10 NS
TNFCD14 cells 53.71 
 3.87 40.56 
 5.43 51.90 
 4.10 NS
ssRNA-stimulated PBMCs, % positive
IL-6CD14 cells 67.76 
 3.70 58.99 
 4.39 37.00 
 5.00 6 mo vs 2 mo: 0.007
TNFCD14 cells 78.30 
 3.20 64.42 
 3.32 69.39 
 5.10 Baseline vs 6 mo: 0.038
Env  gag–stimulated PBMCs, % positive
IL-6CD4 cells 1.71 
 0.94 1.62 
 0.58 3.37 
 1.70 NS
TNFCD4 cells 3.37 
 1.70 2.66 
 0.39 5.07 
 1.24 NS
Plasma cytokine concentrations, pg/mL
IL-6 5.78 
 2.66 2.42 
 0.80 1.18 
 0.21 Baseline vs 2 mo: 0.048
TNF 8.55 
 1.46 8.85 
 2.42 27.41 
 7.78 NS
Data are presented as mean 
 SE.
NS indicates not significant.
Figure 6. Plasma LPS levels are reduced in HCQ-
treated patients. Plasma LPS concentrations in HIV-
infected INRs at baseline (), after 6 months (ms) of
HCQ treatment (u), and 2 months after HCQ interruption
(f). Mean values, SE, and P values are indicated.
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followed at regular time intervals; results from the follow-up will at
least in part clarify these issues.
In conclusion, our data suggest that HCQ has beneficial effects
on TLR/LPS-mediated immune activation, the possible cause of
lack of CD4 T-cell recovery and of associated comorbidity in
INRs. HCQ could be considered to be a useful immunomodulating
drug in particular groups of HIV-infected patients.
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